YL529, a novel, orally available multikinase inhibitor, potently inhibits angiogenesis and tumour growth in preclinical models

BACKGROUND AND PURPOSE: Targeted chemotherapy using small-molecule inhibitors of angiogenesis and proliferation is a promising strategy for cancer therapy. EXPERIMENTAL APPROACH: YL529 was developed via computer-aided drug design, de novo synthesis and high-throughput screening. The biochemical, pha...

Täydet tiedot

Tallennettuna:
Bibliografiset tiedot
Päätekijät: Xu, Youzhi, Lin, Hongjun, Meng, Nana, Lu, Wenjie, Li, Guobo, Han, Yuanyuan, Dai, Xiaoyun, Xia, Yong, Song, Xiangrong, Yang, Shengyong, Wei, Yuquan, Yu, Luoting, Zhao, Yinglan
Aineistotyyppi: Artigo
Kieli:Inglês
Julkaistu: Blackwell Publishing Ltd 2013
Aiheet:
Research Papers
Linkit:https://ncbi.nlm.nih.gov/pmc/articles/PMC3753834/
https://ncbi.nlm.nih.gov/pubmed/23594209
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1111/bph.12216
Tagit: Lisää tagi
Ei tageja, Lisää ensimmäinen tagi!

Samankaltaisia teoksia